Novartis AG 2023 Form 20-F Summary
Business context and reporting period
Novartis filed its annual report on January 31, 2024, for the fiscal year ended December 31, 2023. The consolidated financial statements are prepared under IFRS Accounting Standards and presented in U.S. dollars. Following the October 2023 spin-off of Sandoz, Novartis operates as a single-segment innovative medicines company focused on cardiovascular, renal and metabolic diseases, immunology, neuroscience and oncology.
The filing does not provide a clearly separated fourth-quarter 2023 income statement. Reported comparisons therefore primarily relate to full-year 2023 versus full-year 2022.
Key financial metrics
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net sales from continuing operations | USD 45.440 billion | USD 42.206 billion | +8% reported; +10% constant currencies |
| Operating income from continuing operations | USD 9.769 billion | USD 7.946 billion | +23% reported; +39% constant currencies |
| Operating margin | 21.5% | 18.8% | +2.7 percentage points |
| Net income from continuing operations | USD 8.572 billion | USD 6.049 billion | +42% reported |
| Basic EPS from continuing operations | USD 4.13 | USD 2.77 | +49% reported |
| Core operating income | USD 16.372 billion | USD 14.794 billion | +11% reported; +18% constant currencies |
| Core operating margin | 36.0% | 35.1% | +0.9 percentage points |
| Net cash flow from operating activities, continuing operations | USD 14.220 billion | USD 13.039 billion | +9% |
| Free cash flow, continuing operations | USD 13.160 billion | USD 12.123 billion | +9% |
| Total net income | USD 14.854 billion | USD 6.955 billion | Not meaningful |
Reported total net income includes a non-cash, non-taxable gain of USD 5.860 billion from the Sandoz spin-off. The continuing-operations effective tax rate was 6.0%, compared with 15.7% in 2022; management states that the 2023 rate benefited from several non-recurring tax items. Excluding those effects, management estimates the rate would have been approximately 15.3%.
Research and development expense increased 24% to USD 11.371 billion, or 25.0% of continuing-operations sales. Reported 2023 intangible-asset impairment charges were approximately USD 3.0 billion.
Revenue drivers and material changes
- Promoted-brand sales increased 21% to USD 31.822 billion, while established-brand sales declined 15% to USD 13.618 billion.
- Major growth products included Entresto at USD 6.035 billion, Kesimpta at USD 2.171 billion, Kisqali at USD 2.080 billion and Pluvicto at USD 980 million.
- Established-brand declines were led by Gilenya, down 54% to USD 925 million, and Lucentis, down 21% to USD 1.475 billion, primarily because of generic or other competition.
- U.S. sales were USD 17.959 billion, or 40% of continuing-operations sales. Europe contributed USD 14.997 billion, or 33%.
- Volume contributed 16 percentage points to sales growth, partly offset by a 4-point negative impact from generic competition and a 2-point negative pricing impact.
- Novartis completed the Sandoz spin-off on October 3, 2023. Sandoz results are presented as discontinued operations for current and prior periods, while the 2023 balance sheet excludes Sandoz assets and liabilities after the distribution.
- Novartis acquired Chinook Therapeutics for approximately USD 3.2 billion upfront and DTx Pharma for approximately USD 0.6 billion upfront, increasing investment in renal and neuroscience pipelines.
Cash flow, liquidity and debt
| Balance-sheet metric | December 31, 2023 |
|---|---|
| Cash and cash equivalents | USD 13.393 billion |
| Marketable securities, time deposits and related instruments | USD 1.035 billion |
| Total liquidity | USD 14.428 billion |
| Total financial debt | USD 24.611 billion |
| Net debt | USD 10.183 billion |
| Equity | USD 46.750 billion |
Net debt increased from USD 7.245 billion at year-end 2022, despite total financial debt declining from USD 26.175 billion. The company had USD 3.3 billion of commercial paper outstanding and an undrawn USD 6.0 billion committed credit facility maturing in September 2025. Moody’s rated Novartis A1/P-1 and S&P rated it AA-/A-1+ at year-end.
Financing outflows included USD 7.3 billion of dividends, USD 8.6 billion of net treasury-share transactions and USD 2.2 billion of bond repayments. The Board proposed a 2023 dividend of CHF 3.30 per share, subject to shareholder approval on March 5, 2024.
Outlook, commentary, risks and unusual items
The filing emphasizes continued growth from Entresto, Kesimpta, Kisqali, Scemblix, Pluvicto and Leqvio; productivity savings from the organizational transformation; and pipeline expansion through internal R&D and acquisitions. It does not provide a clear standalone FY2024 revenue or earnings guidance figure in the supplied filing text.
- Entresto was selected for the first U.S. Medicare drug-price negotiation program and is subject to ongoing patent litigation. Novartis filed a constitutional challenge to the Inflation Reduction Act pricing provisions.
- Patent expiry and generic or biosimilar competition remain significant risks, particularly for established brands and products such as Gilenya, Lucentis and other mature medicines.
- R&D execution, clinical-trial outcomes, regulatory approvals, reimbursement, product safety, manufacturing quality and supply continuity could materially affect results.
- The company recorded substantial impairments, including approximately USD 3.0 billion on intangible assets, and carries significant goodwill and intangible assets that remain sensitive to sales forecasts, competition, discount rates and regulatory outcomes.
- Legal and regulatory contingencies include product-liability actions, antitrust and pricing investigations, the IRA litigation, Tasigna litigation and other governmental or commercial proceedings. Management states that provisions are adequate, but additional losses could be material to a particular period.
- Other risks include foreign-exchange volatility, healthcare cost containment, customer concentration, cybersecurity and data privacy, geopolitical tensions, climate change, tax-law changes and implementation of major IT systems.
- The Sandoz spin-off generated a material accounting gain but also reduced reported equity through a USD 14.0 billion dividend-in-kind distribution and changed the comparability of balance-sheet and operating data.
Most important facts for an investor to verify
- Reconcile continuing-operations performance with total-company results and exclude the USD 5.860 billion Sandoz spin-off gain when assessing recurring earnings.
- Review the sustainability of growth in Entresto, Kesimpta, Kisqali, Pluvicto, Scemblix and Leqvio, including access, reimbursement and competitive trends.
- Assess the timing and potential impact of patent challenges and generic competition, especially for Entresto and mature established brands.
- Evaluate the effect of the USD 3.0 billion intangible-asset impairments and the sensitivity of remaining goodwill and intangible assets to forecast assumptions.
- Monitor net debt of USD 10.183 billion, upcoming bond maturities, commercial-paper funding and the decline in liquidity to USD 14.428 billion.
- Review the proposed CHF 3.30 dividend, ongoing share buybacks and their implications for capital allocation and leverage.
- Examine contingent liabilities, including USD 6.083 billion of undiscounted R&D commitments and USD 3.8 billion of commitments for acquisitions and intellectual property, most of which may be payable in 2024.
- Confirm that the reported FY2023 figures are not being interpreted as standalone Q4 results, which the filing text does not separately provide.